Molecular Approaches to Vaccines and Immune Monitoring
joint with B Cell-T Cell Interactions
Organizer(s): Peter D. Kwong, Brandon DeKosky and Jeffrey B. UlmerDate: February 10 - 14, 2019
Location: Keystone Resort, Keystone, CO, USA
Vaccines address public health issues ranging from pandemic outbreaks to childhood disease. Despite this diversity, molecular approaches are beginning to find broad application. This Keystone Symposia conference seeks to bring together antibody aficionados, B cell immunologists, structural biologists, and vaccine developers from government, academia, biotechnology, and major pharmaceutical companies to review the utility of structure-based vaccine design and antibody-based immune monitoring, and in doing so hope to transform standard approaches of vaccine development. This meeting aims (1) to provide examples of the ”antibody-to-vaccine” paradigm for RSV, CMV and other pathogens that have resisted standard vaccinology; (2) to describe procedures whereby B cells can be taught to make the right antibodies; (3) to describe molecular approaches for vaccine improvement; and (4) to discuss how molecular approaches can be used to speed development (as may be needed, for example, in the case of pandemics) and to reduce developmental and regulatory costs (for vaccines in general and in particular to enable provision to the developing world). Overall, we seek to integrate molecular approaches for vaccine development and read-out with other transformative advances including mRNA delivery, next-generation sequencing of B cell transcripts, and control of B cell-T cell interactions. This conference will be held jointly with a Keystone Symposia conference on B Cell-T Cell Interactions and several shared sessions will highlight synergistic areas of research between these communities.
Scholarship Deadline: October 23 2018
Discounted Abstract Deadline: October 23 2018
Abstract Deadline: November 7 2018
Discounted Registration Deadline: December 6 2018
We gratefully acknowledge additional support from these exhibitors at this conference:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Merck & Co., Inc.
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI143056-01
Funding for this conference was made possible (in part) by 1R13AI143056-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.